Imlifidase for highly sensitized kidney transplant patients
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests the drug imlifidase for people who are highly sensitized (have many antibodies) and waiting for a kidney transplant. It aims to help them receive a kidney from a deceased donor even if they have a positive crossmatch (a test that would normally stop the transplant).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be an adult (18 years or older).
- You must be a candidate for a kidney transplant.
- You must be highly sensitized, meaning you have many antibodies against donor kidneys.
- You must be eligible for imlifidase, which requires having at least one HLA antibody (A, B, DR, or DQ) listed.
- You must be waiting for a kidney from a deceased donor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a special immune-resetting treatment can help patients who have developed too many antibodies against donor kidneys get access to a compatible kidney transplant. The treatment uses chemotherapy and stem cell transplantation to 'reset' your immune system so it stops rejecting potential donor kidneys.
This study looks at how memory B cells (a type of immune cell) relate to antibodies against HLA in people waiting for a kidney transplant. It aims to better understand immune responses, which could help improve transplant matching and outcomes.
This trial tests a new medicine called imlifidase that quickly removes harmful antibodies from the blood. It is given to children before a kidney transplant to make the donated kidney more likely to be accepted, especially when standard desensitisation methods have failed.
This trial tests a new drug, OM336, to reduce antibodies that make it hard to find a matching kidney for transplant. It may help people who have been waiting a long time for a kidney or who have a living donor but their antibodies attack the donor kidney.
This study tests whether a medication called belimumab can help people who are highly sensitized (their immune system has many antibodies against donor organs) become eligible for kidney transplant by improving how doctors understand their antibody patterns. The goal is to help these patients access transplants more easily.
This trial tests a specific “induction” treatment to help people who have stronger immune reactions from past sensitizing events during a kidney transplant. It may help improve how well the transplant works and how safely the immune system is managed.
Hear when a new Kidney Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.